Dr. Paul W. Rhyne leads a bioanalytical group for Q2 Solutions, a Quintiles Quest Joint Venture. Dr. Rhyne has more than 15 years of scientific leadership experience in laboratory operations, clinical biomarkers, large molecule PK analysis and Immunogenicity assessment. He obtained his Ph.D. at the University of Tennessee Memphis and completed three years of post-doctoral studies at St. Jude Children’s Research Hospital. Dr. Rhyne was an Associate Director at Bristol-Myers Squibb Company, a Senior Director at Tandem laboratories, and has held many senior leadership positions at Upstate Biotechnology and Amplistar Inc. A noted industry expert in clinical biomarkers and large molecule bioanalytical analysis, he has published many scientific publications in peer-reviewed journals. Dr. Rhyne is an active member of the American Association of Pharmaceutical Scientists, including serving on programming committees, a steering committee for a translational biomarker focus group, and as chair of the biomarker discussion group.